- Home
- CELH vs ITCI Comparison
CELH vs ITCI Comparison
Compare CELH & ITCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELH
- ITCI
- Stock Information
- Founded
- CELH 2004
- ITCI 2002
- Country
- CELH United States
- ITCI United States
- Employees
- CELH N/A
- ITCI N/A
- Industry
- CELH Beverages (Production/Distribution)
- ITCI Biotechnology: Pharmaceutical Preparations
- Sector
- CELH Consumer Staples
- ITCI Health Care
- Exchange
- CELH Nasdaq
- ITCI Nasdaq
- Market Cap
- CELH 6.8B
- ITCI 8.7B
- IPO Year
- CELH N/A
- ITCI N/A
- Fundamental
- Price
- CELH $26.87
- ITCI $126.89
- Analyst Decision
- CELH Strong Buy
- ITCI Buy
- Analyst Count
- CELH 18
- ITCI 13
- Target Price
- CELH $50.22
- ITCI $100.31
- AVG Volume (30 Days)
- CELH 7.2M
- ITCI 2.9M
- Earning Date
- CELH 02-27-2025
- ITCI 02-20-2025
- Dividend Yield
- CELH N/A
- ITCI N/A
- EPS Growth
- CELH 47.74
- ITCI N/A
- EPS
- CELH 0.72
- ITCI N/A
- Revenue
- CELH $1,370,868,000.00
- ITCI $613,728,000.00
- Revenue This Year
- CELH $5.39
- ITCI $48.41
- Revenue Next Year
- CELH $15.69
- ITCI $38.26
- P/E Ratio
- CELH $37.37
- ITCI N/A
- Revenue Growth
- CELH 19.36
- ITCI 46.08
- 52 Week Low
- CELH $25.23
- ITCI $62.78
- 52 Week High
- CELH $99.62
- ITCI $128.00
- Technical
- Relative Strength Index (RSI)
- CELH 43.85
- ITCI 87.18
- Support Level
- CELH $26.08
- ITCI $80.83
- Resistance Level
- CELH $30.27
- ITCI $128.00
- Average True Range (ATR)
- CELH 1.35
- ITCI 2.57
- MACD
- CELH -0.01
- ITCI 4.45
- Stochastic Oscillator
- CELH 26.57
- ITCI 97.65
About CELH Celsius Holdings Inc.
Celsius Holdings plays in the energy drink subsegment of the global nonalcoholic beverage market, with 96% of revenue concentrated in North America. Celsius' products contain natural ingredients and a metabolism-enhancing formulation, appealing to fitness and active lifestyle enthusiasts. The firm's portfolio includes its namesake Celsius Originals beverages, Celsius Essentials line (containing aminos), and Celsius On-the-Go powder packets. Celsius dedicates its efforts to branding and innovation, while it utilizes third parties for the manufacturing, packaging, and distribution of its products. In 2022, Celsius forged a 20-year distribution agreement with PepsiCo, which holds an 8.5% stake in the business.
About ITCI Intra-Cellular Therapies Inc.
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.